Form 4: Bicara Therapeutics COO Sells Shares Under 10b5-1 Plan

Bicara Therapeutics President and COO Ryan Cohlhepp sold 12,500 shares of common stock after exercising options, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Ryan Cohlhepp, President and COO, and a Director of Bicara Therapeutics Inc. (BCAX), engaged in transactions involving the company's common stock.
• On November 21, 2025, Cohlhepp exercised options to acquire 8,000 shares of common stock at an exercise price of $3.7898 per share.
• Concurrently, Cohlhepp sold a total of 12,500 shares of common stock (8,000 shares and 4,500 shares) at a weighted average price of $18.047 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
• Following these transactions, Cohlhepp beneficially owns 193,641 shares of common stock directly.
• Cohlhepp also holds 149,334 stock options, which vest in sixteen equal quarterly installments following August 8, 2023, contingent on continued service.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the sale is pre-planned under a 10b5-1 plan, which mitigates immediate negative interpretation, it still represents a reduction in insider ownership. The significant profit for the executive on the exercised options does not directly reflect company performance or future prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than a reaction to recent company news.
• The exercise of options at $3.7898 and subsequent sale at a weighted average price of $18.047 demonstrates a significant profit for the reporting person on the exercised shares.

Negatives

• An insider sale of 12,500 shares, even if pre-planned, reduces the direct ownership stake of a key executive.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale by a key executive, even if pre-planned, could be perceived negatively by some shareholders, potentially leading to minor downward pressure on the stock price. However, the pre-planned nature under Rule 10b5-1 reduces the implication of a lack of confidence.

Key Dates

Recommendation

The filing details a pre-planned insider sale by a key executive. While insider sales can sometimes signal a lack of confidence, the execution under a Rule 10b5-1 plan adopted months prior suggests the sale is for personal financial planning rather than a reaction to new, negative company developments. Without additional information on the company's fundamentals or future prospects, this specific transaction alone does not warrant a change from a 'hold' position. Investors should monitor future company performance and other insider activity.

Keywords

Bicara Therapeutics, BCAX, Ryan Cohlhepp, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Executive Compensation